GlassScriptPhysician profile
Jamal Z Abdin
NPI 1043201940
$3,084.76
in general payments reported to CMS, 2019-2025
28 companies · $548 in 2025
The $548 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $687 · 2021: $759 · 2022: $341 · 2023: $221 · 2024: $198 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.40 | 2021-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $440.64 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $344.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.85 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $232.94 | 2020-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $137.70 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.79 | 2020-2022 | |
| Glaxosmithkline, LLC. | $113.03 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $99.34 | 2020-2021 | |
| Abbott Laboratories | $81.48 | 2022-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $73.55 | 2020-2021 | |
| Mylan Specialty L.P. | $70.92 | 2019-2023 | Yupelri |
| Allergan, INC. | $67.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $59.95 | 2019-2021 | |
| Astellas Pharma US INC | $57.17 | 2019-2024 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $48.05 | 2019-2020 | |
| Genentech USA, INC. | $39.83 | 2020-2021 | |
| Viatris Specialty LLC | $38.46 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $38.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.22 | 2021 | |
| Idorsia Pharmaceuticals US INC | $29.17 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $27.32 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.44 | 2022 | |
| Dexcom, INC. | $25.24 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.92 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.60 | 2020 | |
| Verona Pharma, INC. | $13.87 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Abdin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.